ATE274520T1 - Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex - Google Patents
Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selexInfo
- Publication number
- ATE274520T1 ATE274520T1 AT96913880T AT96913880T ATE274520T1 AT E274520 T1 ATE274520 T1 AT E274520T1 AT 96913880 T AT96913880 T AT 96913880T AT 96913880 T AT96913880 T AT 96913880T AT E274520 T1 ATE274520 T1 AT E274520T1
- Authority
- AT
- Austria
- Prior art keywords
- ligands
- pct
- nucleic acid
- selex
- systematic
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 5
- 230000009897 systematic effect Effects 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 6
- 108020004707 nucleic acids Proteins 0.000 abstract 6
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 2
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- -1 nucleic acid compounds Chemical class 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/434,425 US5789157A (en) | 1990-06-11 | 1995-05-03 | Systematic evolution of ligands by exponential enrichment: tissue selex |
| US08/437,667 US5864026A (en) | 1990-06-11 | 1995-05-03 | Systematic evolution of ligands by exponential enrichment: tissue selex |
| US08/433,585 US5763566A (en) | 1990-06-11 | 1995-05-03 | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
| US08/434,001 US5712375A (en) | 1990-06-11 | 1995-05-03 | Systematic evolution of ligands by exponential enrichment: tissue selex |
| PCT/US1996/006060 WO1996034875A1 (en) | 1995-05-03 | 1996-05-01 | Systematic evolution of ligands by exponential enrichment: tissue selex |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE274520T1 true ATE274520T1 (de) | 2004-09-15 |
Family
ID=27503827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96913880T ATE274520T1 (de) | 1995-05-03 | 1996-05-01 | Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6114120A (de) |
| EP (1) | EP0823914B1 (de) |
| AT (1) | ATE274520T1 (de) |
| AU (1) | AU732961B2 (de) |
| CA (2) | CA2219807C (de) |
| DE (1) | DE69633227T2 (de) |
| WO (1) | WO1996034875A1 (de) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716580B2 (en) * | 1990-06-11 | 2004-04-06 | Somalogic, Inc. | Method for the automated generation of nucleic acid ligands |
| AU727460B2 (en) * | 1995-05-03 | 2000-12-14 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
| US6068829A (en) | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
| US5856085A (en) * | 1995-12-01 | 1999-01-05 | The Penn State Research Foundation | Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity |
| CA2220785A1 (en) * | 1997-12-02 | 1999-06-02 | Noureddine Rouissi | Selective technique for rapid identification of proteins and genes and uses thereof |
| US20070166741A1 (en) * | 1998-12-14 | 2007-07-19 | Somalogic, Incorporated | Multiplexed analyses of test samples |
| US6232287B1 (en) | 1998-03-13 | 2001-05-15 | The Burnham Institute | Molecules that home to various selected organs or tissues |
| US20030054360A1 (en) * | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
| CA2259745A1 (en) * | 1999-01-19 | 2000-07-19 | Guy Tremblay | Generation of oligonucleotide libraries representative of genomes or expressed mrnas (cdnas) and use thereof |
| DE10019154A1 (de) * | 2000-04-18 | 2001-10-31 | Univ Eberhard Karls | Zellbindende Nukleinsäuremoleküle (Aptamere) |
| US7452964B2 (en) | 2001-09-07 | 2008-11-18 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides against placenta and adipose tissues |
| US20040170955A1 (en) | 2000-09-08 | 2004-09-02 | Wadih Arap | Human and mouse targeting peptides identified by phage display |
| US7420030B2 (en) | 2000-09-08 | 2008-09-02 | The Board Of Regents Of The University Of Texas System | Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
| AU2002257076A1 (en) | 2001-03-19 | 2002-10-03 | President And Fellows Of Harvard College | Nucleic acid shuffling |
| US7807408B2 (en) * | 2001-03-19 | 2010-10-05 | President & Fellows Of Harvard College | Directed evolution of proteins |
| PT1401853E (pt) | 2001-05-25 | 2010-12-07 | Univ Duke | Modulador de oligonucleotídeos |
| US8030465B2 (en) | 2001-06-29 | 2011-10-04 | Medimolecular Pty Ltd | Nucleic acid ligands to complex targets |
| WO2003070190A2 (en) * | 2002-02-19 | 2003-08-28 | Syntherica Corporation | Surrogate antibodies and methods of preparation and use thereof |
| US7727969B2 (en) * | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| WO2005059509A2 (en) * | 2003-12-12 | 2005-06-30 | Saint Louis University | Biosensors for detecting macromolecules and other analytes |
| DE102004021707A1 (de) * | 2004-04-30 | 2005-11-24 | Cytotools Gmbh | Verfahren zur Isolierung von spezifischen Molekülen, die hochselektiv an ausgewählte Zielmoleküle binden |
| US7795009B2 (en) * | 2005-06-15 | 2010-09-14 | Saint Louis University | Three-component biosensors for detecting macromolecules and other analytes |
| US8956857B2 (en) | 2005-06-06 | 2015-02-17 | Mediomics, Llc | Three-component biosensors for detecting macromolecules and other analytes |
| US8945840B2 (en) | 2005-06-10 | 2015-02-03 | Saint Louis University | Methods for the selection of aptamers |
| US7811809B2 (en) * | 2005-06-15 | 2010-10-12 | Saint Louis University | Molecular biosensors for use in competition assays |
| US20090130650A1 (en) * | 2006-02-17 | 2009-05-21 | Weihong Tan | Methods for the production of highly sensitive and specific cell surface probes |
| US20090117549A1 (en) * | 2006-07-18 | 2009-05-07 | Weihong Tan | Aptamer-based methods for identifying cellular biomarkers |
| EA200970250A1 (ru) | 2006-09-05 | 2010-02-26 | Медарекс, Инк. | Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения |
| EP2486941B1 (de) | 2006-10-02 | 2017-03-15 | E. R. Squibb & Sons, L.L.C. | CXCR4-bindende humane Antikörper und deren Verwendungen |
| BRPI0717902A2 (pt) | 2006-12-01 | 2013-10-29 | Medarex Inc | "anticorpo monoclonal humano isolado, composição, conjugado anticorpo-molécula parceria, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para prepar um anticorpo anti-cd22, método para inibir o desenvolvimento de uma célula tumoral que expressa cd22 e método para tratar uma doença inflamatória ou autoimuneem um indivíduo" |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| JP2010513306A (ja) | 2006-12-14 | 2010-04-30 | メダレックス インコーポレーティッド | Ｃｄ７０に結合するヒト抗体およびその使用 |
| US20110136099A1 (en) * | 2007-01-16 | 2011-06-09 | Somalogic, Inc. | Multiplexed Analyses of Test Samples |
| US7964356B2 (en) * | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| AU2008262384B9 (en) | 2007-06-05 | 2014-11-27 | Yale University | Inhibitors of receptor tyrosine kinases and methods of use thereof |
| US8703416B2 (en) | 2008-07-17 | 2014-04-22 | Somalogic, Inc. | Method for purification and identification of sperm cells |
| CA2744003C (en) | 2008-11-21 | 2016-03-15 | Mediomics Llc | Biosensor for detecting multiple epitopes on a target |
| ME02842B (de) | 2009-03-05 | 2018-01-20 | Squibb & Sons Llc | Cadm1-spezifische vollständig humane antikörper |
| EA030182B1 (ru) | 2009-04-20 | 2018-07-31 | Оксфорд Байотерепьютикс Лтд. | Антитела, специфические для кадгерина-17 |
| WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| US20120231004A1 (en) | 2009-10-13 | 2012-09-13 | Oxford Biotherapeutic Ltd. | Antibodies |
| US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| BR112012019902A2 (pt) | 2010-02-10 | 2019-09-24 | Novartis Ag | "método e compostos para o crescimento muscular" |
| CA2787483C (en) | 2010-02-12 | 2018-03-06 | Saint Louis University | Molecular biosensors capable of signal amplification |
| ES2640960T3 (es) | 2011-06-28 | 2017-11-07 | Oxford Biotherapeutics Ltd. | Anticuerpos para ADP-ribosil ciclasa 2 |
| US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
| AU2013340414B2 (en) | 2012-10-23 | 2019-05-02 | Caris Science, Inc. | Aptamers and uses thereof |
| EP2935628B1 (de) | 2012-12-19 | 2018-03-21 | Caris Life Sciences Switzerland Holdings GmbH | Zusammensetzungen und verfahren für aptamer-screening |
| AR097102A1 (es) | 2013-08-02 | 2016-02-17 | Pfizer | Anticuerpo anti-cxcr4 y conjugados de anticuerpo y fármaco |
| US10274484B2 (en) | 2014-09-12 | 2019-04-30 | Mediomics Llc | Molecular biosensors with a modular design |
| EP3332812A1 (de) | 2016-12-07 | 2018-06-13 | Rheinische Friedrich-Wilhelms-Universität Bonn | Nukleinsäurebasierte anordnung und verwendung der anordnung in der krebstherapie |
| WO2018158398A1 (en) | 2017-03-02 | 2018-09-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to nectin-4 and uses thereof |
| WO2021092651A1 (en) * | 2019-11-14 | 2021-05-20 | i-ZUM-X Pty Ltd | Method of detection of fibrin clots |
| WO2021116119A1 (en) | 2019-12-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
| CN115551553A (zh) | 2020-05-12 | 2022-12-30 | Inserm(法国国家健康医学研究院) | 治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法 |
| WO2023170296A1 (en) | 2022-03-11 | 2023-09-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Nucleic acid system to specifically reprogram b and t cells and uses thereof |
| EP4584291A1 (de) | 2022-09-08 | 2025-07-16 | Institut National de la Santé et de la Recherche Médicale | Antikörper mit spezifität gegen ltbp2 und verwendungen davon |
| WO2025224297A1 (en) | 2024-04-26 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to tgfbi and uses thereof |
| WO2025242732A1 (en) | 2024-05-21 | 2025-11-27 | Institut National de la Santé et de la Recherche Médicale | Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes |
| WO2025257181A1 (en) | 2024-06-11 | 2025-12-18 | Institut National de la Santé et de la Recherche Médicale | Antibodies targeting trans-active response dna-binding protein-43 (tdp-43) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3588239T3 (de) * | 1985-03-30 | 2007-03-08 | Kauffman, Stuart A., Santa Fe | Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren |
| WO1989006694A1 (en) * | 1988-01-15 | 1989-07-27 | Trustees Of The University Of Pennsylvania | Process for selection of proteinaceous substances which mimic growth-inducing molecules |
| WO1991014843A1 (en) * | 1990-03-19 | 1991-10-03 | Lee David G | Improved high security axial pin tumbler lock |
| CA2084987C (en) * | 1990-06-11 | 2007-02-13 | Gilead Sciences, Inc. | Nucleic acid ligands |
| US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5688935A (en) * | 1990-06-11 | 1997-11-18 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
| US5750342A (en) * | 1990-06-11 | 1998-05-12 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands of tissue target |
| US5763566A (en) * | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue SELEX |
| US5712375A (en) * | 1990-06-11 | 1998-01-27 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: tissue selex |
| EP0572529A4 (de) * | 1991-02-21 | 1994-11-02 | Gilead Sciences Inc | Spezifisches aptamer für biomolekülen und verfahren zu dessen produktion. |
| AU4842693A (en) * | 1992-09-11 | 1994-04-12 | Duke University | Method for deriving epitopes |
| CA2169536A1 (en) * | 1993-09-08 | 1995-03-16 | Gilead Sciences, Inc. | Nucleic acid ligands and improved methods for producing the same |
-
1996
- 1996-05-01 US US08/945,909 patent/US6114120A/en not_active Expired - Fee Related
- 1996-05-01 CA CA002219807A patent/CA2219807C/en not_active Expired - Lifetime
- 1996-05-01 EP EP96913880A patent/EP0823914B1/de not_active Expired - Lifetime
- 1996-05-01 AT AT96913880T patent/ATE274520T1/de not_active IP Right Cessation
- 1996-05-01 WO PCT/US1996/006060 patent/WO1996034875A1/en not_active Ceased
- 1996-05-01 CA CA002645735A patent/CA2645735A1/en not_active Abandoned
- 1996-05-01 AU AU56707/96A patent/AU732961B2/en not_active Ceased
- 1996-05-01 DE DE69633227T patent/DE69633227T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU5670796A (en) | 1996-11-21 |
| DE69633227T2 (de) | 2005-09-15 |
| EP0823914A1 (de) | 1998-02-18 |
| CA2219807C (en) | 2008-12-30 |
| EP0823914A4 (de) | 2003-02-26 |
| CA2645735A1 (en) | 1996-11-07 |
| DE69633227D1 (de) | 2004-09-30 |
| CA2219807A1 (en) | 1996-11-07 |
| WO1996034875A1 (en) | 1996-11-07 |
| US6114120A (en) | 2000-09-05 |
| AU732961B2 (en) | 2001-05-03 |
| EP0823914B1 (de) | 2004-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE274520T1 (de) | Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex | |
| EP1493825A3 (de) | Verfahren zur Herstellung von Nukleinsäureliganden | |
| Wilkins et al. | Proteogenomic monitoring of Geobacter physiology during stimulated uranium bioremediation | |
| DE69942485D1 (de) | Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems | |
| EP0876387A4 (de) | Verfahren zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren | |
| Hunter | Discovering the first tyrosine kinase | |
| ATE159429T1 (de) | Methode zum überbringen von agenzien an zielzellen | |
| DE69816815D1 (de) | Verfahren zur reinigung von milchsäure | |
| ATE156861T1 (de) | Verfahren zur extraktion von intrazellulären komponenten | |
| ATE476505T1 (de) | Verfahren zur isolierung von nukleinsäuren mit verwendung von ethylenglykol-multimeren | |
| TR199701501T1 (xx) | D���k enerjili hidrojen y�ntemleri ve yap�lar�. | |
| BR112023025730A2 (pt) | Sistemas de transpóson-crispr para modificação de dna, sistema ou kit, composição, célula, método para integração de dna e uso do dito sistema | |
| ATE333502T1 (de) | Verfahren zur herstellung von nukleinsäure- und polypeptidbanken durch in vivo rekombination und ihre verwendungen | |
| EP1889910A3 (de) | Systematische Evolution von Liganden durch exponentielle Anreicherung: Photoselektion von Nukleinsäureliganden und Lösungs-SELEX | |
| DE69213207D1 (de) | Verfahren zur haaranalyse | |
| ATE223971T1 (de) | Neue methoden zum auffinden von liganden- und ziel-biomolekülen | |
| ATE227996T1 (de) | Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod | |
| BG94474A (bg) | Метод за разделяне на органични вещества | |
| DE69632472D1 (de) | Verfahren und zusammensetzung zur herstellung von austrocknungstoleranten sporen von paecitomyces fumosoroseus | |
| Gronauer et al. | A photocrosslinking probe to capture the substrates of caseinolytic protease P | |
| DE69105811D1 (de) | Verfahren zur Extraktion von bestimmten Nukleinsäurefragmenten. | |
| Stolarik | From field to factory: The historiography of Slovak immigration to the United States | |
| EP0888374A4 (de) | Nukleinsäureliganden mit hoher affinität für die proteine des komplementsystems | |
| Kerr | Did an asteroid leave its mark in Montana bones? | |
| Moedritzer | A review of:“Phosphorus-31 NMR-Principles and Applications, David G. Gorenstein, Ed., Academic Press, Orlando, FL, 1985, $79.00, xiv+ 604 pp.” |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |